- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08.06. | Vor Biopharma Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 08.06. | Vor Biopharma: Telitacicept Receives NMPA Approval for the Treatment of Sjögren's Disease in China | 1 | GlobeNewswire (USA) | ||
| 08.06. | Vor Biopharma: Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China | 394 | GlobeNewswire (Europe) | First and only approved BAFF/APRIL-targeting therapy for IgA nephropathy (IgAN) Approval based on positive interim Phase 3 TELIGAN results generated by collaborator RemeGen and recently published... ► Artikel lesen | |
| 01.06. | Vor Biopharma: Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| 13.05. | Vor Biopharma reports Q1 results | 3 | Seeking Alpha | ||
| 13.05. | Vor Biopharma: Vor Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update | 838 | GlobeNewswire (Europe) | Enrollment on track for Phase 3 UPSTREAM MG trial of telitacicept in generalized myasthenia gravis patients with topline results anticipated in 1H27 Enrollment ongoing for Phase 3 UPSTREAM SjD of... ► Artikel lesen | |
| VOR BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 13.05. | Vor Biopharma Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 07.05. | Wall Street Analysts Believe Vor Biopharma (VOR) Could Rally 124.59%: Here's is How to Trade | 5 | Zacks | ||
| 04.05. | Vor Biopharma: Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 15.04. | H.C. Wainwright senkt Kursziel für Vor Biopharma auf 31 US-Dollar | 1 | Investing.com Deutsch | ||
| 15.04. | H.C. Wainwright lowers Vor Biopharma price target to $31 | 1 | Investing.com | ||
| 08.04. | Stifel reiterates Vor Biopharma stock rating on drug potential | 1 | Investing.com | ||
| 08.04. | Stifel bekräftigt Kaufempfehlung für Vor Biopharma wegen Medikamentenpotenzial | 1 | Investing.com Deutsch | ||
| 01.04. | Vor Biopharma: Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| 30.03. | Stifel cuts Vor Biopharma stock price target on financing assumptions | 2 | Investing.com | ||
| 30.03. | Stifel senkt Kursziel für Vor Biopharma aufgrund neuer Finanzierungsannahmen | 2 | Investing.com Deutsch | ||
| 30.03. | Vor Biopharma reports Q4 results | 2 | Seeking Alpha | ||
| 30.03. | Vor Bio doses first patient in phase 3 Sjögren's disease trial | 1 | Investing.com | ||
| 30.03. | Vor Biopharma: Vor Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update | 379 | GlobeNewswire (Europe) | First patient dosed in UPSTREAM SjD, a global Phase 3 clinical trial assessing telitacicept in primary Sjögren's disease $75 million private placement strengthens balance sheet and supports telitacicept... ► Artikel lesen | |
| 30.03. | Vor Biopharma: Vor Bio Doses First Patient in Global Phase 3 UPSTREAM SjD Registrational Trial of Telitacicept in Primary Sjögren's Disease | 372 | GlobeNewswire (Europe) | BOSTON, March 30, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the dosing of the first... ► Artikel lesen |
1 2 3 Weiter >>
44 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 2,248 | +0,49 % | VALNEVA SE: Valneva Announces Successful Outcome of its Annual General Meeting | Dr. Gerd Zettlmeissl is appointed as Chair of the Board of Directors Lyon (France), June 25, 2026 - Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 47,830 | +0,25 % | CRISPR Therapeutics AG: CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results | ZUG, Switzerland and BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the first quarter ended March 31, 2026. "The first quarter reflected... ► Artikel lesen | |
| VIVOSIM LABS | 1,060 | -0,93 % | VivoSim Labs, INC. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | ||
| EDITAS MEDICINE | 2,800 | -1,41 % | Editas Medicine, Inc.: Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting | CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, shared new preclinical... ► Artikel lesen | |
| VIVORYON THERAPEUTICS | 1,090 | +1,87 % | Vivoryon Therapeutics N.V. Reports Q1 2026 Financial Results and Provides Business Update | Vivoryon Therapeutics N.V. Reports Q1 2026 Financial Results and Provides Business Update
Compelling kidney function data and meta-analysis from two Phase 2 studies with varoglutamstat presented... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 15,880 | +1,02 % | Sarepta Moves Closer To FDA Approval For Duchenne Muscular Dystrophy Drugs | ||
| GERON | 1,103 | +0,05 % | Geron Corporation Reports First Quarter 2026 Financial Results and Recent Business Highlights | Achieved $51.8 million in RYTELO- (imetelstat) net product revenue in Q1 2026, an increase of 8% compared to the fourth quarter 2025 Reiterated 2026 RYTELO net product revenue and total operating... ► Artikel lesen | |
| TRAWS PHARMA | 0,826 | -2,00 % | Traws Pharma, Inc.: Traws Pharma Provides Updated Guidance on Influenza Prophylaxis Program | NEWTOWN, Pa., June 22, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW, Traws, the Company), a clinical-stage biopharmaceutical company developing novel therapies for critical global viral... ► Artikel lesen | |
| UNIQURE | 40,050 | -0,62 % | uniQure Inc.: uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares | LEXINGTON, Mass. and AMSTERDAM, June 25, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs... ► Artikel lesen | |
| SOL GLOBAL INVESTMENTS | 0,026 | -100,00 % | SOL Global Investments Corp.: SOL Global Announces Resignation of Pad Gopal, Chief Financial Officer and Interim Chief Executive Officer | Toronto, Ontario--(Newsfile Corp. - June 25, 2026) - SOL Global Investments Corp. (CSE: SOL) (OTC Pink: SOLCF) (FSE: 9SB) ("SOL Global" or the "Company"), announces that Mr. Pad Gopal has provided... ► Artikel lesen | |
| FATE THERAPEUTICS | 2,438 | +2,61 % | Globaler Biotech-Wettlauf und die Zukunft der Plattformstrategie - Warum Mesoblast auf den Pfaden von großen Konzernen wie Merck KGaA wandert | ||
| ZAI LAB LTD ADR | 16,700 | 0,00 % | Zai Lab Limited: Zai Lab Presents New Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Rapid and Robust Intracranial Responses in Small Cell Lung Cancer with Brain Metastases and Promising Activity in Other Neuroendocrine Carcinomas | Zoci, a potential first-in-class DLL3-targeting antibody drug conjugate, showed a 53.7% confirmed intracranial objective response rate (iORR) for small cell lung cancer (SCLC) with brain metastases... ► Artikel lesen | |
| TRINITY BIOTECH | 0,378 | -2,85 % | Trinity Biotech plc: Trinity Biotech Terminates Standby Equity Purchase Agreement with Yorkville | DUBLIN, June 29, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial stage biotechnology company focused on human diagnostics and the development of innovative solutions addressing... ► Artikel lesen | |
| VERASTEM | 3,459 | +3,59 % | RBC Kapital bestätigt Rating für Verastem: G12D-Inhibitor mit über 250 % Kurspotenzial | ||
| VOYAGER THERAPEUTICS | 3,196 | +4,44 % | Voyager Therapeutics (VYGR) is Amongst the Best Stocks Under $10, With More Than 50% Upside |
Das Unternehmen VOR BIOPHARMA INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +0,11 % bei einem Aktienkurs von 18,430 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VOR BIOPHARMA INC finden Sie auf Wallstreet Online.